Streptomyces species are experts in the production of bioactive secondary metabolites; however, their taxonomy has fallen victim of the tremendous interest

Whole-genome sequencing (WGS) is revolutionizing clinical bacteriology. However, bacterial typing remains investigated by reference techniques with inherent limitations. This stresses the need for alternative methods providing robust and accurate sequence type (ST) classification. This study optimized and evaluated a GridION nanopore sequencing protocol, adapted for the PromethION platform. Forty-eight Escherichia coli clinical isolates with diverse STs were sequenced to assess two alternative typing methods and resistance profiling applications. Multi-locus sequence typing (MLST) was used as the reference typing method. Genomic relatedness was assessed using Average Nucleotide Identity (ANI) and digital DNA-DNA Hybridization (DDH), and cut-offs for discriminative strain resolution were evaluated. WGS-based antibiotic resistance prediction was compared to reference Minimum Inhibitory Concentration (MIC) assays. We found ANI and DDH cut-offs of 99.3% and 94.1%, respectively, which correlated well with MLST classifications and demonstrated potentially higher discriminative resolution than MLST. WGS-based antibiotic resistance prediction showed categorical agreements of ≥ 93% with MIC assays for amoxicillin, ceftazidime, amikacin, tobramycin, and trimethoprim-sulfamethoxazole. Performance was suboptimal (68.8–81.3%) for amoxicillin-clavulanic acid, cefepime, aztreonam, and ciprofloxacin. A minimal sequencing coverage of 12× was required to maintain essential genomic features and typing accuracy. Our protocol allows the integration of PromethION technology in clinical laboratories, with ANI and DDH proving to be accurate and robust alternative typing methods, potentially offering superior resolution. WGS-based antibiotic resistance prediction holds promise for specific antibiotic classes.

Background: The marine environment hosts the vast majority of living species and marine microbes that produce natural products with great potential in providing lead compounds for drug development. With over 70% of Earth’s surface covered in water and the high interaction rate associated with liquid environments, this has resulted in many marine natural product discoveries. Our improved understanding of the biosynthesis of these molecules, encoded by gene clusters, along with increased genomic information will aid us in uncovering even more novel compounds. Results: We introduce MariClus (https://www.mariclus.com), an online user-friendly platform for mining and visualizing marine gene clusters. The first version contains information on clusters and the predicted molecules for over 500 marine-related prokaryotes. The user-friendly interface allows scientists to easily search by species, cluster type or molecule and visualize the information in table format or graphical representation. Conclusions: This new online portal simplifies the exploration and comparison of gene clusters in marine species for scientists and assists in characterizing the bioactive molecules they produce. MariClus integrates data from public sources, like GenBank, MIBiG and PubChem, with genome mining results from antiSMASH. This allows users to access and analyze various aspects of marine natural product biosynthesis and diversity.

Objectives: To assess the feasibility and reproducibility of predicting antimicrobial resistance (AMR) in Escherichia coli from MALDI-TOF mass spectrometry data using a standardized, open-source machine learning (ML) workflow, we systematically compared four ML algorithms, evaluated the impact of culture conditions, extract storage, and spectral preprocessing on model performance, and validated results through nested cross-validation with statistical significance testing. Methods: A total of 282 clinical E. coli isolates were analyzed. Two MALDI-TOF MS datasets were generated from freshly cultured extracts (T₁) and recultured isolates one year later (T₃), yielding 4468 spectra. A third dataset from the T₁ extracts stored at −20 °C for one year (T₂) was evaluated for spectral stability but excluded from primary modeling likely due to storage-induced degradation. Protein spectra (m/z 2000–15,000) were preprocessed using an in-house developed MALDI-TOF preprocessing pipeline (MTPP) comprising variance stabilization, Savitzky–Golay smoothing, SNIP baseline correction, TIC normalization, LOWESS alignment, and MAD-based peak detection (SNR ≥ 3), yielding 121 m/z features. Four classifiers—Random Forest (RF), Logistic Regression, Support Vector Machine, and Gradient Boosting—were trained to predict resistance to 11 antibiotics using nested cross-validation: outer GroupShuffleSplit (5-fold, isolate-level) for evaluation and inner GroupKFold for recursive feature elimination (RFECV) and hyperparameter tuning (RandomizedSearchCV). Classification thresholds were optimized via the precision–recall curve. Model performance was assessed using AUROC, AUPRC, F1-score, Matthews Correlation Coefficient (MCC), and bootstrap 95% confidence intervals (1000 replicates). Pairwise model comparisons were tested with McNemar’s chi-squared test. Results: Among the 12 antibiotics included in the analysis (meropenem excluded for absence of resistance), resistance prevalence ranged from 1.1% (colistin) to 59.9% (amoxicillin). Colistin was subsequently also excluded from ML modeling due to insufficient resistant isolates (n = 3), leaving 11 antibiotics for prediction. The best predictive performance was observed for ciprofloxacin (AUROC 0.76 [95% CI 0.74–0.77]; F1 0.54; MCC 0.38) and ceftazidime (AUROC 0.68 [0.65–0.71]; F1 0.36; MCC 0.29), using 13 and 37 RFECV-selected features, respectively. Amoxicillin achieved the highest F1-score (0.76), driven by high recall (0.98) but modest AUROC (0.58). No meaningful predictive signal was detected for amikacin, cefepime, or tigecycline (AUROC ≤ 0.57, F1 ≤ 0.17), attributable to extreme class imbalance, and no robust multi-peak resistance signature was detected in this dataset. McNemar’s test confirmed that RF significantly outperformed Logistic Regression for all antibiotics (p < 0.01), while Gradient Boosting performed comparably to RF for ciprofloxacin (p = 0.17) and ceftazidime (p = 0.28). Frozen extracts (T₂) produced lower spectral similarity and were excluded from model training; the aligned T₁₊₃ dataset yielded the most stable performance across metrics. Conclusions: Machine learning analysis of MALDI-TOF spectra enables reproducible AMR prediction for selected antibiotics in E. coli, with ciprofloxacin and ceftazidime showing the strongest signal. Nested isolate-level cross-validation, multi-model comparison with statistical testing, and open-source code provide a transparent, reproducible foundation for integrating ML-assisted MALDI-TOF analysis into diagnostic AMR surveillance. Extract storage at −20 °C degrades spectral quality and should be avoided in ML training workflows.